Supriya Lifescience: Final Dividend of ₹1.00 per Share for FY26 Recommended
Supriya Lifescience recommended a final dividend of ₹1.00 per share for FY26. The dividend payment is subject to shareholder approval at the AGM. Tax will be deducted at source for both resident and non-resident shareholders, with specific documentation required for beneficial tax rates. Shareholders must update details by July 15, 2026.
The dividend recommendation is a positive development for shareholders. However, the extensive details on tax deduction at source (TDS) and the requirement for shareholders to submit specific documents by a deadline add a procedural layer that slightly moderates the impact.
The announcement is a standard dividend declaration and related tax information, which is routine for listed companies. While a dividend is generally positive, the detailed tax implications and procedural requirements make the overall sentiment neutral.
Supriya Lifescience Limited has announced that its Board of Directors, in a meeting held on May 27, 2026, recommended a Final Dividend of ₹1.00 per equity share (50%) for the Financial Year 2025-26. This recommendation is subject to the approval of the shareholders at the upcoming Annual General Meeting (AGM).
As per the Income Tax Act, 2025, the final dividend for FY25-26, to be paid in FY26-27, will be taxable in the hands of the shareholders. The company will deduct tax at source (TDS) at the time of dividend payment, with rates varying based on the shareholder's residential status and submitted documentation. For resident shareholders, TDS will generally be 10%, unless exempt. For non-resident shareholders, TDS will be 20% plus applicable surcharge and cess, with an option to avail Double Taxation Avoidance Agreement (DTAA) benefits if more favorable, requiring specific documentation like a Tax Residency Certificate (TRC) and other declarations.
Shareholders are urged to ensure their details, including PAN, residential status, email/postal address, and bank account details, are complete and updated with their depository participant or the Company's Registrar & Share Transfer Agent (RTA), MUFG Intime India Private Limited. All necessary documents and declarations for claiming beneficial tax rates must be submitted to the RTA on or before July 15, 2026. The company reserves the right to reject incomplete or discrepant documents. Shareholders holding shares under multiple accounts with a single PAN will have the higher applicable tax rate applied to their entire holding.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.